Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (anti-β2GP) are important cause of venous and arterial thrombosis and other occlusive vascular diseases. The prevalen...Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (anti-β2GP) are important cause of venous and arterial thrombosis and other occlusive vascular diseases. The prevalence of these antibodies in SLE patients at the time of diagnosis is not known in Indian SLE patients. This study was conducted to evaluate the prevalence of ACA and anti-β2GP autoantibodies in SLE patients and to correlate them with disease activity and immune parameters such as C3, C4 and CRP levels. where 85 SLE patients referred from Rheumatology Department, KEM hospital, Mumbai were studied. SLE disease activity was evaluated by SLE Disease Activity Index (SLEDAI) score at the time of evaluation. All patients studied were in an active stage of disease of which 37.6% patients had renal disorders, which were categorized as Lupus Nephritis (LN) and 62.3% patients did not show any renal manifestations (non-LN). ACA and anti-β2GP autoantibodies, to IgG and IgM subclasses were tested by ELISA. C3, C4 and CRP levels were detected by nephelometer. It was observed that 12.9% patients were IgG-ACA and IgM-ACA positive and ACA positivity was noted more among LN group Anti-β2GP autoantibody positivity was 27.1% for IgG and 31.8% for IgM., IgG-anti-β2GP antibodies were slightly higher in non-LN patients, whereas a higher incidence of IgM-anti-β2GP antibodies were detected in LN patients. Hence detection both ACA and anti-β2GP antibodies along with associated immune parameters were helpful to evaluate their possible association with disease severity in SLE patients. A long term follow up of patients having ACA and anti-β2GP antibodies without thrombotic event is also needed to detect their possible thrombotic event in future along with their clinical presentation.展开更多
目的探讨血清抗C1q抗体在系统性红斑狼疮(SLE)患者狼疮肾炎(LN)以及疾病活动中的临床价值。方法采用ELISA法检测102例SLE患者以及35例正常对照组血清中抗C1q抗体水平,比较分析其与SLE病情活动指数(SLEDAI)评分、疾病活动性指标抗双链DNA...目的探讨血清抗C1q抗体在系统性红斑狼疮(SLE)患者狼疮肾炎(LN)以及疾病活动中的临床价值。方法采用ELISA法检测102例SLE患者以及35例正常对照组血清中抗C1q抗体水平,比较分析其与SLE病情活动指数(SLEDAI)评分、疾病活动性指标抗双链DNA(ds-DNA)抗体、补体C3、C4水平、超敏C反应蛋白(hs-CRP)以及肾脏损害指标24 h尿蛋白定量(24 h UPQ)、肌酐(Cr)、尿素氮(BUN)的相关性,以及通过联合检测抗ds-DNA抗体以及抗核小体抗体(Anu A)判断其在SLE中的临床价值。结果总体SLE患者抗C1q抗体敏感性为55.9%,特异性为94.3%,在SLE中其抗体水平显著高于正常对照组,其中疾病活动LN组、疾病稳定LN组和疾病活动非LN组抗C1q抗体水平明显高于疾病稳定非LN组水平,差异有统计学意义(P<0.01),而疾病稳定LN组、疾病活动LN组与疾病活动非LN组之间比较,差异无统计学意义。在疾病活动期中,抗C1q抗体水平与SLEDAI评分、ds-DNA、hs-CRP呈正相关性(P<0.05),与C4呈负相关性(P<0.05),C3和24 h UPQ仅在疾病活动LN组中呈相关性;在疾病稳定期中,抗C1q抗体水平只有在疾病活动和疾病稳定LN组中与24 h UPQ呈正相关性,与C3、C4呈负相关性。联合检测抗ds-DNA抗体、Anu A、抗C1q抗体显著提高稳定期LN的诊断价值。结论抗C1q抗体对SLE的诊断和LN判断有重要临床价值,抗C1q抗体参与了SLE肾脏损害的发病机制,联合检测抗dsDNA抗体、Anu A、抗C1q抗体有助于SLE稳定期肾脏损害的诊断。展开更多
文摘Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (anti-β2GP) are important cause of venous and arterial thrombosis and other occlusive vascular diseases. The prevalence of these antibodies in SLE patients at the time of diagnosis is not known in Indian SLE patients. This study was conducted to evaluate the prevalence of ACA and anti-β2GP autoantibodies in SLE patients and to correlate them with disease activity and immune parameters such as C3, C4 and CRP levels. where 85 SLE patients referred from Rheumatology Department, KEM hospital, Mumbai were studied. SLE disease activity was evaluated by SLE Disease Activity Index (SLEDAI) score at the time of evaluation. All patients studied were in an active stage of disease of which 37.6% patients had renal disorders, which were categorized as Lupus Nephritis (LN) and 62.3% patients did not show any renal manifestations (non-LN). ACA and anti-β2GP autoantibodies, to IgG and IgM subclasses were tested by ELISA. C3, C4 and CRP levels were detected by nephelometer. It was observed that 12.9% patients were IgG-ACA and IgM-ACA positive and ACA positivity was noted more among LN group Anti-β2GP autoantibody positivity was 27.1% for IgG and 31.8% for IgM., IgG-anti-β2GP antibodies were slightly higher in non-LN patients, whereas a higher incidence of IgM-anti-β2GP antibodies were detected in LN patients. Hence detection both ACA and anti-β2GP antibodies along with associated immune parameters were helpful to evaluate their possible association with disease severity in SLE patients. A long term follow up of patients having ACA and anti-β2GP antibodies without thrombotic event is also needed to detect their possible thrombotic event in future along with their clinical presentation.
文摘目的探讨血清抗C1q抗体在系统性红斑狼疮(SLE)患者狼疮肾炎(LN)以及疾病活动中的临床价值。方法采用ELISA法检测102例SLE患者以及35例正常对照组血清中抗C1q抗体水平,比较分析其与SLE病情活动指数(SLEDAI)评分、疾病活动性指标抗双链DNA(ds-DNA)抗体、补体C3、C4水平、超敏C反应蛋白(hs-CRP)以及肾脏损害指标24 h尿蛋白定量(24 h UPQ)、肌酐(Cr)、尿素氮(BUN)的相关性,以及通过联合检测抗ds-DNA抗体以及抗核小体抗体(Anu A)判断其在SLE中的临床价值。结果总体SLE患者抗C1q抗体敏感性为55.9%,特异性为94.3%,在SLE中其抗体水平显著高于正常对照组,其中疾病活动LN组、疾病稳定LN组和疾病活动非LN组抗C1q抗体水平明显高于疾病稳定非LN组水平,差异有统计学意义(P<0.01),而疾病稳定LN组、疾病活动LN组与疾病活动非LN组之间比较,差异无统计学意义。在疾病活动期中,抗C1q抗体水平与SLEDAI评分、ds-DNA、hs-CRP呈正相关性(P<0.05),与C4呈负相关性(P<0.05),C3和24 h UPQ仅在疾病活动LN组中呈相关性;在疾病稳定期中,抗C1q抗体水平只有在疾病活动和疾病稳定LN组中与24 h UPQ呈正相关性,与C3、C4呈负相关性。联合检测抗ds-DNA抗体、Anu A、抗C1q抗体显著提高稳定期LN的诊断价值。结论抗C1q抗体对SLE的诊断和LN判断有重要临床价值,抗C1q抗体参与了SLE肾脏损害的发病机制,联合检测抗dsDNA抗体、Anu A、抗C1q抗体有助于SLE稳定期肾脏损害的诊断。